Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Artelo Biosciences ( (ARTL) ) has provided an announcement.
On December 31, 2025, Artelo Biosciences, Inc. convened but immediately adjourned its 2025 annual meeting of stockholders without conducting any business because it lacked a quorum of votes. The annual meeting is now scheduled to reconvene virtually on January 30, 2026, with the same record date of December 10, 2025, and previously submitted proxies still valid unless revoked. The company also plans to add a new proposal for shareholders to ratify the appointment of Malone Bailey LLP as independent auditor for the fiscal year ending December 31, 2026, while otherwise keeping the existing slate of proposals unchanged, a procedural step that may be important for governance continuity and auditor oversight but does not alter the company’s operational outlook.
The most recent analyst rating on (ARTL) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
The score is primarily driven down by weak financial performance (no revenue, widening losses, ongoing cash burn, and negative equity) and bearish technicals (strong downtrend and negative momentum). Corporate event risk (Nasdaq delisting determination) further pressures the outlook, while valuation provides limited support due to continued losses and no dividend.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Average Trading Volume: 628,076
Technical Sentiment Signal: Sell
Current Market Cap: $2.46M
For a thorough assessment of ARTL stock, go to TipRanks’ Stock Analysis page.